NCI Opens Up Phase III Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

BETHESDA, Maryland-Oncologists nationwide now have access to National Cancer Institute (NCI) clinical trials under a new policy intended to encourage a wider participation in phase III studies. The new policy makes it easier for oncologists to become credentialed as investigators and to enroll their patients in the advanced studies through NCI’s Cancer Trials Support Unit (CTSU). Previously, access to NCI’s clinical trials was limited to members of NCI’s cooperative groups.

BETHESDA, Maryland—Oncologists nationwide now have access to National Cancer Institute (NCI) clinical trials under a new policy intended to encourage a wider participation in phase III studies. The new policy makes it easier for oncologists to become credentialed as investigators and to enroll their patients in the advanced studies through NCI’s Cancer Trials Support Unit (CTSU). Previously, access to NCI’s clinical trials was limited to members of NCI’s cooperative groups.

Oncologists can use the web-based CTSU to download protocols, case report forms, and other documents.

Interested physicians can enter the program through a two-phase application and credentialing process, which will include a site visit to ensure an oncologist’s capability to meet regulatory requirements and collect research data successfully. Information on the project is available online at www.ctsu.org, or by calling 1-888-823-5923.

Recent Videos
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Related Content